"Super Aspirin" Holds Long-Term Benefits For Some Patients Who Undergo Balloon Angioplasty

August 13, 1997

Patient Profiles, Drug Costs And Other Interventional Alternatives Are Issues To Consider When Deciding Who Should Receive This Therapy.While innovative techniques and catheters, including coronary stents, have dramatically improved success rates for nonsurgical coronary revascularization, complications following balloon angioplasty remain an important problem associated with mortality. An intravenous "super aspirin" called abciximab (ReoPro™, Centocor, Inc., Malvern, PA) administered in the catheterization laboratory before an angioplasty can prevent platelets from sticking to arterial walls and reclogging vessels after the procedure. Results of a multicenter study published in the August 13 issue of The Journal of the American Medical Association (JAMA) demonstrate a favorable effect on long-term outcome and survival in selected patients treated with ReoPro™.

In an editorial that accompanies the study, David L. Fischman, MD, associate professor of medicine, division of cardiology, Jefferson Medical College, Philadelphia, and associate director, cardiac catheterization laboratory at Thomas Jefferson University Hospital, recognizes the vast advantages of ReoPro™ but points out that patient profiles, drug costs and other interventional alternatives are issues to consider when deciding who should receive this "super aspirin."

In his editorial, Dr. Fischman notes that the multicenter study, which is a three-year follow-up to an initial study of ReoPro™, led by Eric J. Topol, MD, of the Cleveland Clinic Foundation, Ohio, shows that the benefits of ReoPro™ are greatest in the highest risk patients with acute heart attack or medically unstable angina. "The Topol study suggests a remarkable 60 percent reduction in mortality at three years in this select group treated with ReoPro™ compared with the group treated with placebo," said Dr. Fischman.

While pretreatment with ReoPro™ is highly effective, its average cost is estimated at $1,350 per patient dose. "The cost of this drug should bring significant attention to the question of who should receive it," said Dr. Fischman. "The issue of cost-effectiveness is vital to understanding whether or not ReoPro™ should be used in lower risk patient populations."

Dr. Fischman suggests that further investigation is necessary to address this issue. "Future development of oral agents similar to ReoPro™ promises to further expand the use of these agents to a broader spectrum of patients with ischemic heart disease," he said.Michael P. Savage, M.D., associate professor of medicine, division of cardiology, Jefferson Medical College, and director of the cardiac catheterization laboratory at Thomas Jefferson University Hospital, contributed to the editorial.

Thomas Jefferson University

Related Angioplasty Articles from Brightsurf:

Ticagrelor was not superior to clopidogrel to reduce heart attack risk during angioplasty
A new study found the rate of heart attack and severe complications before, during or soon after elective surgery to open a blocked artery was similar between patients treated with clopidogrel and those who received the more potent antiplatelet medication ticagrelor.

Study finds significant variability in doctors' angioplasty death rates
Some doctors have higher or lower than expected death rates from coronary angioplasty procedures, also known as percutaneous coronary intervention (PCI); however, doctors should not be judged solely on the rate of patients who die from the procedure.

Beta-blockers following angioplasty show little benefit for some older patients
Following coronary angioplasty, beta-blockers did not significantly improve mortality rates or reduce the number of future cardiovascular incidents for older patients with stable angina but no history of heart attack or heart failure, according to a study published today in the JACC: Cardiovascular Interventions.

Sleep disorders may predict heart events after angioplasty
People who have had procedures to open blocked heart arteries after acute coronary syndrome (ACS) may have a higher risk of death, heart failure, heart attack and stroke if they have sleep disorders, such as sleep apnea, compared to those who don't.

Reasons for hospital-level variations in bleeding post-angioplasty are unclear
The use of bleeding avoidance strategies has only a modest effect on the variation in bleeding rates post-angioplasty among hospitals performing this procedure, leaving about 70 percent of the causes for this variation unexplained, according to a study published today in JACC: Cardiovascular Interventions.

US prediction models for kidney injury following angioplasty hold up in Japan
Models developed by the American College of Cardiology NCDR CathPCI Registry to predict the likelihood of angioplasty patients developing acute kidney injury and acute kidney injury requiring dialysis have proven to be effective among patients in Japan.

IV beta blockers before angioplasty are safe, but offer no clinical benefit
Giving intravenous beta blockers before performing a coronary angioplasty in patients who had experienced the deadliest form of heart attack -- ST-segment elevation myocardial infarction (STEMI) -- was safe but did not reduce heart attack severity or improve blood flow from the heart's main pumping chamber, according to research presented at the American College of Cardiology's 65th Annual Scientific Session.

Life-threatening bowel ischemia can often be treated by balloon angioplasty
Acute mesenteric ischemia (AMI) can be successfully treated with endovascular therapy such as balloon angioplasty, according to research from the University of Eastern Finland.

Radial access used less than femoral approach for emergency angioplasty
Although using the radial artery as the access point for angioplasty has been linked to reduced bleeding compared to use of the femoral artery, only a small number of high-risk heart attack patients who undergo rescue angioplasty -- emergency procedures following failed therapy with clot-busting drugs -- are treated by radial access, according to a study published today in the Journal of the American College of Cardiology: Cardiovascular Interventions.

Use of rarely appropriate angioplasty procedures declined sharply
The number of angioplasty procedures classified as rarely appropriate declined sharply between 2010 and 2014, as did the number of those performed on patients with non-acute conditions, according to a study published today in the Journal of the American Medical Association and simultaneously presented at a meeting of the American Heart Association in Orlando.

Read More: Angioplasty News and Angioplasty Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.